Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
Globe Life's second quarter of fiscal year 2026 was defined by a sharp acceleration in health insurance premiums and improved mortality in life insurance, which together lifted underwriting margins. Management attributed the performance to strong Medicare Supplement sales and rate increases at United American, as well as favorable mortality in the Direct to Consumer and Liberty National life divisions. However, the key American Income Life division saw a 5% decline in producing agents, even as its premiums grew 5%, and Direct to Consumer net sales slipped 4% amid AI-related shifts in search behavior, creating a tension between current earnings strength and future growth visibility.
Revenue
$1.6B
+8.00% YoY
EPS (Diluted)
$3.65
+19.67% YoY
Source: SEC XBRL
Globe Life (GL) reported Q2 FY2026 revenue of $1.6B, up 8.0% year over year. GL's fiscal Q2 FY2026 corresponds to calendar Q2 2026.
Last 4 quarters: 1 beat
| Quarter | Actual EPS (USD) | Consensus (USD) | Result |
|---|---|---|---|
| Jun 2026This filing | 3.61 | 3.79 | Miss -4.7% |
| Mar 2026 | 3.43 | 3.58 | Miss -4.1% |
| Dec 2025 | 3.39 | 3.54 | Miss -4.2% |
| Sep 2025 | 4.81 | 4.68 | Beat +2.8% |
Adjusted (non-GAAP) EPS of $3.61 versus the $3.79 analyst consensus — a -4.7% miss for Jun 2026. Analyst consensus is quoted on the adjusted (non-GAAP) basis the street uses. GAAP diluted EPS for this quarter was $3.65.
3 reported segments · SEC XBRL
Segment revenue totals $1.59B, which is the $1.59B of consolidated revenue on the income statement.
Compiled by AI from 10-Q Item 2 of this filing
Health net sales increased 30% year-over-year to $177 million in the first half of 2026, with United American's net sales up 68% due to favorable demographics and a shift from Medicare Advantage to Medicare Supplement plans.
Source: 10-Q Item 2 MD&A
The life insurance underwriting margin remained strong at 41% of premium for the six months, as net policy obligations fell to 35% of premium from 37%, reflecting improved mortality results.
Source: 10-Q Item 2 MD&A
The Direct to Consumer division saw its underwriting margin rise to 31% from 27% even as net sales fell 4%, driven by favorable mortality. The division is adapting to AI-driven changes in consumer search behavior.
Source: 10-Q Item 2 MD&A
The largest life distribution channel, American Income Life, saw premiums increase 5%, but average producing agent count declined 5% year-over-year. Agent counts did show incremental growth from the first to second quarter.
Source: 10-Q Item 2 MD&A
The company repurchased 2.6 million shares for $378 million in the first half, contributing to an 18% increase in book value per share to $78.18.
Source: 10-Q Item 2 MD&A
Compiled by AI from this SEC filing · 2 high, 3 medium, 0 low
American Income Life accounts for 54% of life premium and its average producing agent count fell 5% year-over-year, highlighting vulnerability to agent attrition. Sustained declines could undermine future premium growth and margin expansion.
Source: 10-Q Item 2 MD&A
Medicare Supplement premiums now represent 47% of health premiums, and the business is subject to regulatory rate approvals and potential changes in Medicare policy. Adverse regulatory actions or competitive shifts in the Medicare Advantage vs. Supplement market could materially impact growth.
Source: 10-Q Item 2 MD&A
The investment segment's excess investment income is sensitive to interest rates, and the portfolio is heavily weighted in fixed maturities. A decrease in rates could compress investment spreads and reduce profitability.
Source: 10-Q Item 2 MD&A
The debt-to-equity ratio stood at 4.13 at quarter-end, reflecting significant reliance on policyholder liabilities and debt financing. High leverage could limit financial flexibility and amplify the impact of adverse business conditions.
Source: 10-Q Balance Sheet (XBRL)
Year-to-date operating cash flow of $735 million was down 0.7% from the prior year, despite a 13.8% increase in net income for the second quarter. This divergence could signal working capital pressures or lower cash conversion efficiency.
Source: 10-Q Cash Flow Statement (XBRL)
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue $B | 1.60 $B | 1.48 $B | +8.00% |
Net Income $M | 287.75 $M | 252.75 $M | +13.85% |
EPS (Basic) $ | 3.71 $ | 3.09 $ | +20.06% |
EPS (Diluted) $ | 3.65 $ | 3.05 $ | +19.67% |
Answers draw on this SEC filing and the data on this page
Expected release date, analyst estimates & what to watch
GL (Globe Life) delivered solid Q1 FY2026 results with revenue growing 5.3% YoY to $1.56B and net income rising 6.3% to $270.5M, while EPS surged 13.1% to $3.45 on a basic basis, reflecting continued earnings growth and capital returns to shareholders.
GL (Globe Life) delivered solid FY2025 results with revenue growing 3.7% to $6.0B and net income rising 8.4% to $1.16B, while EPS surged 19.0% to $14.27 driven by share buybacks and improved profitability.
Other companies in Life & Health Insurance